Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
The immunomodulatory oligodendrocyte.
Measuring Water Content using T2 Relaxation at 3T: Phantom Validations and Simulations.
Towards a predictive model for Guillain-Barré syndrome.
Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation.
Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation.
Diffusion MRI abnormalities detection with orientation distribution functions: A multiple sclerosis longitudinal study.
Assessing dalfampridine efficacy in the physician's office.
Microglial P2 Purinergic Receptor and Immunomodulatory Gene Transcripts Vary By Region, Sex, and Age in the Healthy Mouse CNS.
Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.
Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
[A case of early systemic lupus erythematosus complicated with optic neuritis].
Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis.
Increased disease severity in non-Western immigrants with multiple sclerosis in Oslo, Norway.
The development of primary central nervous system B-cell lymphoma in multiple sclerosis.
New Poteintial Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies.
Autoimmunity in multiple sclerosis need not be abnormal.
The conceptualization and development of a patient-reported neurogenic bladder symptom score.
Autoantibodies in neuroimmunological diseases; relevance of fine specificity.
Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.
Hesperidin, nobiletin, and tangeretin are collectively responsible for the anti-neuroinflammatory capacity of tangerine peel (Citri reticulatae pericarpium).
Ophthalmic manifestations of systemic diseases-part 2: metabolic, infections, granulomatoses, demyelination, and skeletal dysplasias.
Serum thyroid-stimulating hormone and anti-thyroglobulin antibody are independently associated with lesions in spinal cord in central nervous system demyelinating diseases.
Behavioral measurement of laser flashblindness in rhesus monkeys.
Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?
Pages
« first
‹ previous
…
563
564
565
566
567
568
569
570
571
…
next ›
last »